Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and ...
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced a major policy shift to reduce reliance on animal testing in the evaluation of monoclonal antibodies and other drugs. The ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ...
The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with human-based methods. The agency said the new approach will aim to improve drug ...
Stem Pharm, a Madison biotech startup, is using lab-created 3D "organoids" to develop a treatment for Alzheimer's disease. In April, the FDA and NIH announced plans to incentivize so-called "new ...
WASHINGTON (AP) — The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions ...
Although new approach methodologies (NAMs) are not that new, they remain a crucial and evolving aspect of the development and production of biopharmaceuticals. “NAMs have been around for 20 years plus ...
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human-Relevant New Approach Methodologies (NAMs) DiNABIOS Applauds Historic U.S. Senate Passage of FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback